Oclusiones venosas retinales

Mitchell, 1996, Prevalence and associations of retinal vein occlusion in Australia, Arch Ophthalmol, 114, 1243, 10.1001/archopht.1996.01100140443012 Klein, 2008, The 15-year cumulative incidence of retinal vein occlusion, Arch Ophthalmol, 126, 513, 10.1001/archopht.126.4.513 Christoffersen, 1999, Pathophysiology and hemodynamics of branch retinal vein occlusion, Ophthalmology, 106, 2054, 10.1016/S0161-6420(99)90483-9 Weinberg, 1994, Arteriovenous crossing as a risk factor in branch retinal vein occlusion, Am J Ophthalmol, 118, 263, 10.1016/S0002-9394(14)72917-4 Scott, 2009, SCORE Study Report 1: baseline association between central retinal thickness and visual acuity in patients with retinal vein occlusion, Ophthalmology, 116, 504, 10.1016/j.ophtha.2008.10.017 Browning, 2007, Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema, Ophthalmology, 114, 525, 10.1016/j.ophtha.2006.06.052 1986, Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial: Branch Vein Occlusion Study Group, Arch Ophthalmol, 104, 34, 10.1001/archopht.1986.01050130044017 1984, Argon laser photocoagulation for macular edema in branch vein occlusion, Am J Ophthalmol., 98, 271, 10.1016/0002-9394(84)90316-7 Lee, 2005, Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion, Retina, 5, 551, 10.1097/00006982-200507000-00001 Chen, 2006, Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion, Am J Ophthalmol, 141, 876, 10.1016/j.ajo.2005.12.011 2009, Arch Ophthalmol, 127, 1115, 10.1001/archophthalmol.2009.233 Prager, 2009, Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial, Br J Ophthalmol, 93, 452, 10.1136/bjo.2008.141085 Kriechbaum, 2008, Intravitreal avastin for macular oedema secondary to retinal vein occlusiona prospective study, Br J Ophthalmol, 92, 518, 10.1136/bjo.2007.127282 Rabena, 2007, Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion, Retina, 27, 419, 10.1097/IAE.0b013e318030e77e Wu, 2009, Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions. Results of the Pan American Collaborative Retina Study Group at 24 Months, Retina, 29, 1396, 10.1097/IAE.0b013e3181bcef53 Campochiaro, 2010, Ranibizumab for macular Edema following Branch Retinal Vein Occlusion, Ophthalmology, 117, 1102, 10.1016/j.ophtha.2010.02.021 1996, Risk factors for central retinal vein occlusion, Arch Ophthalmol, 114, 545, 10.1001/archopht.1996.01100130537006 Hayreh, 1990, Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase, Graefes Arch Clin Exp Ophthalmol, 228, 201, 10.1007/BF00920022 1997, Natural history and clinical management of central retinal vein occlusion, Arch Ophthalmol, 115, 486, 10.1001/archopht.1997.01100150488006 1995, A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report, Ophthalmology, 102, 1434, 10.1016/S0161-6420(95)30848-2 Aiello, 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N Engl J Med, 331, 1480, 10.1056/NEJM199412013312203 Pe'er, 1998, Vascular endothelial growth factor upregulation in human central retinal vein occlusion, Ophthalmology, 105, 412, 10.1016/S0161-6420(98)93020-2 1995, Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report, Ophthalmology, 102, 1425, 10.1016/S0161-6420(95)30849-4 2009, Arch Ophthalmol, 127, 1101, 10.1001/archophthalmol.2009.234 Rosenfeld, 2005, Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion, Ophthalmic Surg Lasers Imaging, 36, 336, 10.3928/1542-8877-20050701-15 Priglinger, 2007, Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial, Retina, 27, 1004, 10.1097/IAE.0b013e3180ed458d Iturralde, 2006, Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study, Retina, 26, 279, 10.1097/00006982-200603000-00005 Costa, 2007, Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study, Retina, 27, 141, 10.1097/IAE.0b013e31802eff83 Ninel, 2008, Long-term safety and efficacy of intravitreal Bevacizumab (Avastin) for the management of central retinal vein occlusion, Retina, 28, 1325, 10.1097/IAE.0b013e318188501f Prager, 2009, Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion:12-month results of a prospective clinical trial, Br. J. Ophthalmol, 93, 452, 10.1136/bjo.2008.141085 Brown, 2010, Ranibizumab for Macular Edema following Central Retinal Vein Occlusion, Ophthalmology, 117, 1124, 10.1016/j.ophtha.2010.02.022